StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) KPIs and segments

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1382.75−32.80 (-2.32%)

Close on Nov 18, 2026Market cap $1.30TP/E 44.9Yield 0.45%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Eli Lilly · năm tài chính kết thúc December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Eli Lilly: 92 chỉ số vận hành, trong đó có Consolidated revenue, Worldwide revenue growth YoY và U.S. revenue growth YoY, lấy từ 157 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Net product revenue($M)
22,65021,40318,45318,30016,33114,72611,60112,02510,57210,3557,7978,290
Cardiometabolic Health($M)2
19,76418,35315,76013,17811,3439,2087,4077,5155,493
United States($M)
12,37611,7429,92410,0578,8678,3636,5776,5275,5175,7164,0904,465
Outside U.S.($M)
7,3886,6115,8364,4354,3112,9802,6312,5791,8901,7991,4031,282
Mounjaro($M)2
10,7239,9438,6626,5155,1993,8423,1133,0911,807
Outside U.S.($M)
5,7255,1524,4303,2672,9651,8971,186899728677286101
United States($M)
4,9984,7914,2324,1433,5503,3022,6562,6312,3852,4141,5202,105
Zepbound($M)2
5,3524,9284,1603,5883,3812,3121,2581,243517
United States($M)
5,2674,8734,1344,2303,5683,3802,3051,9081,2581,243517176
Outside U.S.($M)
86552630202700000
Oncology($M)2
2,6002,5702,2682,4082,4141,9482,2322,1591,810
United States($M)
1,5181,4731,2281,5121,3751,4191,0461,4681,2941,2759981,107
Outside U.S.($M)
1,0821,0971,0401,0951,0339949021,084938884812777
Collaboration and other revenue($M)
1,7471,5711,3469921,2708321,1271,5088689489721,064
Jardiance($M)2
1,5781,2321,1147699596901,0141,199686770687798
Outside U.S.($M)
796615602302535308705734351341318329
United States($M)
781616512466424382310465336429368469
Verzenio($M)2
1,5111,4741,3021,4701,4891,1591,3691,3321,050
United States($M)
8978457069978809296581,043879861638775
Outside U.S.($M)
614629596608590560501513490471412370
Immunology($M)2
1,4351,4171,2031,3621,2561,0881,1861,082834
United States($M)
801790619912773701578767694600397605
Outside U.S.($M)
634627584629589555510524492483437499
Other cardiometabolic health($M)2
1,2071,0319051,0649809451,0491,1651,026
United States($M)
7295544465246185565357236037546022,607
Outside U.S.($M)
4794774604924464254104964464124241,454
Other oncology($M)2
1,0891,096966937924789863827760
United States($M)
6216285225154954903884264164143601,034
Outside U.S.($M)
4684684444884434344005724474134001,152
Trulicity($M)2
9041,2199191,0521,0921,0951,3011,2461,456
United States($M)
6019086006937077447718009358771,0821,255
Outside U.S.($M)
302312318344345348325451366369374413
Taltz($M)2
856856733902848762880825604
United States($M)
539539417724583549477665600539347538
Outside U.S.($M)
316317315328318299285286279285257247
Other immunology($M)2
579561470461408326306258230
Outside U.S.($M)
318310269302271256225238212197180773
United States($M)
26225120218719015210210293.860.450.1226
Neuroscience($M)2
444429382316344272352340389
United States($M)
384325293320240248189224201192163183
Outside U.S.($M)
5910489139769683170151148226180
Other($M)2
154205187337202213263208242
Outside U.S.($M)
97122130114292119113145156155196161
United States($M)
5784567745831004610752.245.795.2
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)19
United States($M)
15,13614,41312,11912,87711,30010,8148,4899,0327,8147,8355,6946,455
Outside U.S.($M)
9,2618,5617,6806,4156,3014,7434,2394,5013,6263,4683,0742,898
Europe($M)
4,4594,1153,6463,0973,4982,5742,3892,4481,6281,4041,4411,338
Rest of world($M)
3,2062,8772,7712,1901,6881,1829971,0641,1081,206893
China($M)
947941693474560466451429460395376377
Japan($M)
648628571654555521402559429463364439
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Consolidated revenue ($M)($M)
22,97419,79919,29217,60115,55812,72913,53311,43911,3038,7689,353
Worldwide revenue growth YoY (%)(%)3
48.0%56.0%43.0%54.0%38.0%45.0%45.0%20.0%36.0%26.0%28.0%
Worldwide volume growth impact YoY (%)(%)
60.0%65.0%46.0%62.0%42.0%53.0%48.0%15.0%27.0%16.0%
Worldwide realized price impact YoY (%)(%)
-13.0%-13.0%-5.0%-10.0%-6.0%-6.0%-4.0%6.0%10.0%10.0%
Worldwide foreign exchange impact YoY (%)(%)
1.0%4.0%4.0%2.0%1.0%-2.0%-1.0%-1.0%
U.S. revenue growth YoY (%)(%)2
33.0%43.0%43.0%45.0%38.0%49.0%40.0%46.0%42.0%28.0%39.0%
U.S. volume growth impact YoY (%)(%)
37.0%49.0%50.0%60.0%46.0%57.0%45.0%35.0%27.0%12.0%12.0%
U.S. realized price impact YoY (%)(%)
-3.0%-7.0%-7.0%-15.0%-8.0%-7.0%-5.0%11.0%15.0%16.0%-3.0%
Outside U.S. revenue growth YoY (%)(%)3
80.0%81.0%43.0%74.0%37.0%38.0%55.0%-12.0%25.0%22.0%10.0%
Outside U.S. volume growth impact YoY (%)(%)
113.0%95.0%38.0%66.0%35.0%46.0%56.0%-10.0%27.0%23.0%10.0%
Outside U.S. realized price impact YoY (%) [Q1–Q3 10-Q & FY 10-K](%)
-36.0%-25.0%3.0%-1.0%-3.0%-1.0%-3.0%
Outside U.S. foreign exchange impact YoY (%)(%)
4.0%11.0%4.0%6.0%3.0%-5.0%-1.0%-3.0%3.0%
Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M)($M)1
9,9438,6627,4096,5155,1993,8423,5303,1133,0911,8072,206
Mounjaro — Worldwide revenue growth YoY (%)(%)
91.0%125.0%110.0%109.0%68.0%113.0%60.0%132.4%64.0%32.0%
Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M)($M)1
4,9284,1604,2613,5883,3812,3121,9071,2581,243517176
Zepbound — Worldwide revenue growth YoY (%)(%)
46.0%80.0%123.0%185.0%172.0%
Trulicity (dulaglutide) — U.S. revenue ($M)($M)1
9086006937077447718009358771,0821,255
Trulicity — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%)
12.0%-16.0%366.0%368.9%374.4%-25.0%-22.0%-31.0%-26.0%-14.0%
Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M)($M)2
1,2321,1147699596901,0141,199686770687798
Jardiance commercial milestone collaboration revenue ($M)($M)
25025002000370
Jardiance — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%)
79.0%10.0%350.5%340.7%318.3%50.0%-2.0%15.0%19.0%30.0%
Verzenio (abemaciclib) — Worldwide revenue ($M)($M)1
1,4741,3021,6041,4701,4891,1591,5551,3691,3321,0501,145
Verzenio — Worldwide revenue growth YoY (%)(%)
-1.0%12.0%3.0%7.0%12.0%10.0%36.0%32.0%44.0%40.0%42.0%
Taltz (ixekizumab) — U.S. revenue ($M)($M)1
539417724583549477665600539347538
Taltz — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%)
1.0%-4.0%279.3%285.3%257.0%21.0%18.0%17.0%15.0%11.0%
Non-major products combined ('Other products' in MD&A) — Worldwide revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)3
3,3222,9106,0176,0275,4885,4161,536682644610698
Non-major products combined — U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)
1,8421,5173,5073,3013,2042,871492326279208203
Non-major products combined — Outside U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)
1,4811,3932,5102,7262,2852,5451,044357364402496
Non-major products combined — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY 10-K](%)
16.0%14.0%6.0%-3.0%196.2%29.0%2.0%1.0%
Humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
620535632539367
Humalog (insulin lispro) — Worldwide revenue YoY (%) [legacy](%)
69.0%35.0%43.0%17.0%-33.0%
Humulin (human insulin) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
280207224206188
Humulin (human insulin) — Worldwide revenue YoY (%) [legacy](%)
61.2%9.0%-18.0%
Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
177162181158185
Basaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy](%)
-10.0%17.0%-25.0%
Cyramza (ramucirumab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
259236249230254
Cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy](%)
5.0%-4.0%-3.0%-9.0%
Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
175152156145150
Erbitux (cetuximab) — Worldwide revenue YoY (%) [legacy](%)
-1.0%-4.0%11.0%
Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
250203192226186
Emgality (galcanezumab) — Worldwide revenue YoY (%) [legacy](%)
20.0%13.0%46.0%6.0%
Olumiant (baricitinib) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
262251228217243
Olumiant (baricitinib) — Worldwide revenue YoY (%) [legacy](%)
8.0%4.0%-5.0%18.0%
Tyvyt (sintilimab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
136150123117114
Tyvyt (sintilimab) — Worldwide revenue YoY (%) [legacy](%)
30.0%19.0%91.0%98.0%
Alimta (pemetrexed) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
44.9
Alimta (pemetrexed) — Worldwide revenue YoY (%) [legacy](%)
-81.0%
Forteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
11869.961.3116
Forteo (teriparatide) — Worldwide revenue YoY (%) [legacy](%)
-19.0%-53.0%-50.0%
Cialis (tadalafil) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
91.587.713978.8
Cialis (tadalafil) — Worldwide revenue YoY (%) [legacy](%)
5.0%-24.0%39.0%
Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
8.8031.743.8
Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy](%)
-98.0%
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1
0
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy](%)
-100.0%
Retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy](%)
14.0%
Consolidated sales rebates and discounts liability ($M)($M)
21,12217,54717,38217,62014,53711,55011,53912,43012,4479,43011,689
Total research and development expense ($M)($M)2
3,8193,5103,8023,4663,3362,7343,0232,7342,7112,5232,562
Early-stage research and discovery expense ($M)($M)
1,4501,2661,4851,2501,1569901,0449951,025852
Late-stage clinical development expense ($M)($M)
2,3682,2442,3162,2162,1801,7441,9791,7391,6861,671
Acquired in-process research and development (IPR&D) charges ($M)($M)1
2,7765845296561541,5721892,826154111620
Cash paid for IPR&D and development milestones ($M)($M)
3,2822044247201071,7572512,82017896.5580
Asset impairment, restructuring and other special charges ($M)($M)
70327984.136503534481.6435068
GAAP gross margin ($M)($M)1
19,70616,22215,92014,59313,11010,50411,1299,2689,1337,0957,565
GAAP gross margin (% of revenue)(%)
85.8%81.9%82.5%82.9%84.3%82.5%82.2%81.0%80.8%80.9%80.9%
Non-GAAP gross margin ($M)($M)2
19,83116,35016,04414,71213,23210,62711,2659,4089,2727,2347,694
Non-GAAP gross margin (% of revenue)(%)
86.3%82.6%83.2%83.6%85.0%83.5%83.2%82.2%82.0%82.5%82.3%
Amortization of intangible assets in cost of sales ($M)($M)
125128124119122123136139139139129
Non-GAAP net income ($M)($M)1
7,4937,6636,7716,3125,6793,0044,8061,0653,5412,3352,249
Non-GAAP diluted earnings per share ($)($)
8.388.557.547.026.313.345.321.183.922.582.49
GAAP effective tax rate (%)(%)1
23.3%16.4%19.7%22.8%16.5%20.2%12.5%38.9%15.6%11.6%12.7%
Non-GAAP effective tax rate (%)(%)
22.2%16.5%19.7%17.7%16.5%20.2%13.2%37.6%16.5%11.9%13.1%
Total inventories, net ($M)($M)2
16,79314,52913,74412,18011,0149,3117,5897,4606,4826,1025,773
Total inventories, gross (FIFO cost before LIFO reserve, $M)($M)3
16,75514,49213,70112,21911,0159,2827,5267,3866,3946,0055,670
Finished goods inventory ($M)($M)
2,6302,2731,9311,5471,3551,2981,2211,114811700792
Work in process (WIP) inventory ($M)($M)
9,9978,4568,1837,2756,5095,2963,9794,0353,7063,6123,249
Raw materials and supplies inventory ($M)($M)
4,1283,7633,5873,3973,1512,6872,3262,2371,8761,6941,630
LIFO inventory valuation reserve ($M)($M)
-38-37-4338.41.40-29.3-63-73.4-87.7-96.5-102
Property and equipment, net ($M)($M)1
29,28626,54024,67522,31620,53018,47417,10216,17214,82913,62412,914
Accumulated depreciation ($M)($M)
13,10312,56012,41112,55412,14711,78911,81611,42811,23511,099
Capital expenditures (additions to property and equipment, $M)($M)
2,9332,3262,5472,0871,6971,5101,4961,3511,2259861,071
Depreciation and amortization expense ($M)($M)
534509586470478463485467414401387
Goodwill ($M)($M)
8,8496,1305,8985,8985,7715,7715,7705,7685,7684,9404,940
Other intangible assets, net ($M)($M)
18,1107,3746,5216,4475,9086,0126,1666,5376,6366,7626,907
Prepaid income taxes ($M)($M)1
13,60011,80012,90018,69016,4007,1004,260
Noncurrent accrued income taxes ($M)($M)
5,4615,2895,8756,2945,6845,3714,0613,8793,4974,1893,849
Long-term debt, noncurrent ($M)($M)1
47,85839,37040,86840,87434,18034,50028,52729,04523,73024,56018,321
Short-term borrowings and current maturities of long-term debt ($M)($M)1
7,0504,0001,6351,6335,7244,0165,1172,0745,1621,6526,905
Commercial paper outstanding ($M)($M)
5,2841,775004,0922,4894,3381,2954,3859856,189
FX forward contracts (not designated as hedging instruments) — Long notional ($M)($M)3
17,86913,29714,2818,755
FX forward contracts (not designated as hedging instruments) — Short notional ($M)($M)
10,1235,5209,2648,848
FX forward contracts (net investment hedges) — Long notional ($M)($M)
246297678,909
Foreign-currency principal notes (designated as net investment hedges) — Notional ($M)($M)
3,6003,6006,0005,300
Dividends paid per share ($)($)1
1.731.731.501.501.501.501.301.301.301.301.13
Cash dividends paid ($M)($M)
1,5461,5481,3461,3461,3471,3461,1681,1711,1721,1691,018
Cash paid for share repurchases ($M)($M)2
1,6012,3561,5087086921,2002,054446000
Share repurchase program total authorization ($M)($M)
15,00015,00015,00015,00015,00015,00015,000
Share repurchase authorization remaining ($M)($M)
7,0008,60010,90012,40013,11013,8001,9802,5002,5002,500
Stock-based compensation expense — Pretax ($M)($M)
201161136151185154142133211159121
Employee Benefit Trust assets ($M)($M)
3,0133,0133,0133,0133,0133,0133,0003,0133,0133,0133,010
U.S. Personal Consumption Expenditures: Health Care — SAAR ($B)(M)
3,7903,7003,6673,6153,5303,4653,4183,3583,2883,2443,159
Revenue ($M)($M)13
22,97419,79919,29217,60115,55812,72913,53311,43911,3038,7689,353
Cost of sales ($M)($M)
3,2683,5773,3723,0082,4482,2252,4042,1712,1701,6741,788
Research and development ($M)($M)
3,8193,5103,8023,4663,3362,7343,0232,7342,7112,5232,562
Marketing, selling, and administrative ($M)($M)
3,4302,9343,1312,7412,7532,4682,4252,1002,1171,9521,926
Asset impairment, restructuring, and other special charges ($M)($M)
70327984.136503534481.6435068
Interest income ($M) [reported separately through Q3 2025]($M)
654048.344.347.837.345.844.5
Other — net, (income) expense ($M)($M)
269-65-108-133-90-239-11162-19827.1121
Income before income taxes ($M)($M)
9,2478,8508,2667,2326,7773,4565,0381,5883,5172,5362,508
Income taxes ($M)($M)
2,1521,4541,6291,6501,116697629618550293319
Net income ($M)($M)
7,0957,3966,6385,5835,6612,7594,4109702,9672,2432,189
Earnings per share — Basic ($)($)
7.958.276.226.303.071.083.292.49
Earnings per share — Diluted ($)($)
7.948.266.216.293.061.073.282.48
Weighted-average shares outstanding — Basic (millions)(M)
892895897898899901901901
Weighted-average shares outstanding — Diluted (millions)(M)
894896899900901905904904
Total assets ($M)($M)7
142,283116,576112,476114,935100,92389,38978,71575,60771,87563,94464,006
Total current assets ($M)($M)6
64,67254,83555,62962,07149,85441,26132,74031,41530,20425,18925,727
Cash and cash equivalents ($M)($M)
8,9505,2827,2689,7923,3763,0933,2683,3693,2242,4602,819
Short-term investments ($M) [through Q3 2025]($M)
122170127155149140126109
Accounts receivable, net ($M)($M)
20,08318,42917,76016,10714,17012,03711,00610,29511,0287,8869,091
Inventories ($M)($M)
16,79314,52913,74412,18011,0149,3117,5897,4606,4826,1025,773
Prepaid expenses and other ($M)($M)
15,36813,63314,31520,24918,02014,6548,3418,2517,1386,3495,541
Other current assets ($M)($M)
8621414727268.872.4266135142139150
Property and equipment, net ($M)($M)
29,28626,54024,67522,31620,53018,47417,10216,17214,82913,62412,914
Goodwill ($M)($M)
8,8496,1305,8985,8985,7715,7715,7705,7685,7684,9404,940
Other intangibles, net ($M)($M)
18,1107,3746,5216,4475,9086,0126,1666,5376,6366,7626,907
Deferred tax assets ($M)($M)
10,02811,3509,9598,9639,4278,5738,0017,3926,6555,6345,477
Sundry / long-term investments ($M)($M)
3,8563,1162,8022,8083,2073,2233,2163,2002,8783,0873,052
Other noncurrent assets ($M)($M)
7,4827,2316,9926,4326,2256,0755,7205,1224,9044,7084,990
Total liabilities ($M)3
Total current liabilities ($M)($M)4
47,74136,63435,22840,14139,02030,06828,37624,67427,12118,59827,293
Short-term borrowings and current maturities of long-term debt ($M)($M)
7,0504,0001,6351,6335,7244,0165,1172,0745,1621,6526,905
Accounts payable ($M)($M)
6,1125,0295,3794,2624,0763,4423,2292,8872,9252,4742,599
Income taxes payable ($M) [through Q3 2025]($M)
9,4446,9586,1761,116
Other current liabilities ($M)($M)
11,6598,6998,4575,2155,0773,7706,3975,5804,2494,1993,281
Long-term debt ($M)($M)
47,85839,37040,86840,87434,18034,50028,52729,04523,73024,56018,321
Other noncurrent liabilities ($M)($M)
7,3444,0853,9703,7772,3452,2883,4792,2392,4712,2712,241
Total equity ($M)($M)6
33,87931,19826,53523,85118,34915,84714,27214,32113,63612,89710,864
Common stock ($M)($M)
588590590591592593592594594594594
Additional paid-in capital ($M)($M)
7,1176,9217,3467,2327,0896,9107,4397,3407,2147,0107,250
Retained earnings ($M)($M)
31,89329,51424,47022,25217,37615,10013,54513,62713,17812,55410,312
Accumulated other comprehensive loss ($M)($M)
-2,761-2,833-2,880-3,206-3,716-3,775-4,322-4,275-4,379-4,300-4,327
Cost of common stock in treasury ($M) [through Q3 2025]($M)
-62.5-55.4-49.5-49.5-32.7-32.7-32.7-44.2
Noncontrolling interests ($M) [through Q3 2025]($M)
57.576.28279.580.773.585.291.8
Net cash provided by operating activities ($M)($M)6
10,6905,3333,2258,8353,0871,6662,4743,7121,4661,166-312
Depreciation and amortization ($M)($M)
534509586470478463485467414401387
Stock-based compensation expense ($M)($M)
201161136151185154142133211159121
Net cash used for investing activities ($M)($M)1
-15,396-3,916-2,802-2,983-1,834-3,353-1,921-4,005-2,199-1,178-2,925
Other investing activities, net ($M)($M)
-127-3156.8-308141111-678373105-48.271.1
Net cash provided by / (used for) financing activities ($M)($M)6
8,426-3,470-2,879531-1,2451,380-2262111,556-3113,545
Dividends paid to shareholders ($M)($M)
1,5461,5481,3461,3461,3471,3461,1681,1711,1721,1691,018
Purchases of common stock / share repurchases ($M)($M)
1,6012,3561,5087086921,2002,054446-0-0-0
Issuances of long-term debt ($M)($M)
8,9410-0.206,70606,461-0.104,96506,4530.50
Repayments of long-term debt ($M)($M)
873750-0.100.10778-0-0.20-0-0
Net change in short-term borrowings ($M)($M)
3,5091,775-0.40-4,0921,603-1,8493,042-3,0893,400-5,2054,594
Other financing activities, net ($M)($M)
-4-591-25.1-29.9-31-686-45.9-47.3-8-390-31.6
Effect of exchange rate changes on cash and equivalents ($M)($M)
-5267-67.132.1275132-429227-59.6-35.5130
Net increase / (decrease) in cash and cash equivalents ($M)($M)
3,668-1,986-2,5246,416283-175-101145763-358438

97 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Eli Lilly and Company operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026).
  • Core operational & financial KPIs (Groups 1–5) cover: (1) Revenue Disaggregation by Product ($60,958M in FY25) vs. Collaboration & Other ($4,221M in FY25), Geography (U.S. $43,481M vs. Outside U.S. $21,698M across Europe $11,558M, Japan $2,132M, China $1,951M & Rest of World $6,057M), and Volume / Realized Price / Foreign Exchange Revenue Growth Drivers across Worldwide, U.S., and Outside U.S. (42 periods FY17–FY26Q2; Q2 2026 WW +48% driven by +52% volume and -6% price); (2) Therapeutic Area & Medicine Revenue across Cardiometabolic Health (Mounjaro $9,943M & Zepbound $4,928M in Q2 2026; $22,965M & $13,542M in FY25, plus Trulicity, Jardiance & Other Cardiometabolic), Oncology (Verzenio $1,474M in Q2 2026; $5,723M in FY25), Immunology (Taltz), Neuroscience, and 18 legacy/established medicines & historical Elanco Animal Health segment; (3) U.S. Gross-to-Net (GTN) Rebates, Discounts & Returns Liability ($21,122M at Q2 2026; 96% U.S.) and full 10-year U.S. GTN Rollforward ($54,757M GTN provision and $48,885M cash rebate payments in FY25), and U.S. Portfolio List (+2.9%) vs. Net Price Realized (39% of list in FY25); (4) R&D Pipeline Expense Split between Early-Stage Research/Discovery ($4,881M in FY25) and Late-Stage Clinical Development ($8,456M in FY25), Acquired IPR&D charges ($2,910M in FY25), Advertising ($2,900M / 5.0% of revenue in FY25), and Restructuring/Impairment; and (5) GAAP vs. Non-GAAP Gross Margin (84.8% GAAP / 85.4% Non-GAAP in Q2 2026), Non-GAAP Net Income & Diluted EPS ($8.41 in Q2 2026; $24.21 in FY25), GAAP vs. Non-GAAP Effective Tax Rates, Current & Deferred Federal/Foreign Taxes, Deferred Tax Assets by attribute, and Unrecognized Tax Benefits ($5,082M at FY25).
  • Groups 6–9 cover Manufacturing, Inventory, PP&E, Intangibles & Leases (LIFO/FIFO Inventories $16,793M net at Q2 2026 including $9,997M WIP, $1,500M pre-launch capitalized inventory, Gross PP&E $37,235M at FY25 including $13,013M Construction in Progress, Geographic Long-Lived Assets across U.S. $18,764M & Ireland $4,321M, Goodwill $8,849M, Other Intangibles $18,110M net with 5-year amortization schedule, and Operating Leases), Debt, Derivatives & Capital Return ($47,858M long-term debt & $5,284M commercial paper at Q2 2026, $17,869M long / $10,123M short FX forward contracts, Dividends, Share Repurchases, SBC & Employee Benefit Trust), Workforce, Compensation, Form 11-K 401(k) & Defined Benefit Pensions (50,000 employees, 23,000 outside U.S., 12,000 in R&D, 9% turnover, 85 training hours, CEO pay ratio 293:1, $15.62B Lilly 401(k) Plan & $634.8M Puerto Rico Savings Plan, and $14.26B Pension PBO / $14.82B Plan Assets across 6 asset classes), and Lilly 30x30 Global Health Reach (40M people in FY25) & Environmental/Safety KPIs (79.3% renewable electricity, 96.8% water recycle rate, Scope 1/2/3 GHG emissions).
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'between 16% and 24% wholesaler revenue concentration' and 'less than 1% product returns / prior-period GTN adjustments' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-10-25.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Therapeutic Area & Medicine Revenue (Key Products & Legacy Portfolio)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Eli Lilly

See a number that looks wrong?